{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T12:53:53Z","timestamp":1782392033326,"version":"3.54.5"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001734","name":"Copenhagen University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001734","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Infertile men have an increased prevalence of metabolic syndrome. Denosumab has been shown to lower HbA1c in older patients with impaired glucose tolerance. We hypothesized that denosumab will lower HbA1c in a cohort of young infertile men.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a secondary analysis of a single-center, placebo-controlled randomized clinical trial comprising infertile men with no serious co-morbidities. Men were randomized 1:1 to receive a single s.c. injection of 60\u00a0mg denosumab or placebo. Prespecified secondary outcome variables included HbA1c, fasting glucose, fasting insulin, C-peptide, while the primary end point semen quality has previously been reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We randomized 100 infertile men and 92 were included in the final analysis. There were no differences between denosumab and placebo groups at day 80 or 160 for HbA1c, LDL, HDL or total cholesterol. For fasting patients (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200944) there were no differences in plasma glucose, plasma insulin, C-peptide, or HOMA-IR. At day 160 alanine aminotransferase was higher in the denosumab group compared to placebo 8.3 U\/L (95% CI 3.3 to 13.3). In a subgroup with high baseline serum cortisol, denosumab reduced HbA1c by 2.5 mmol\/mol (95% CI -5.0 to -0.1) compared to placebo.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>A single dose of denosumab had no effect on glucose- or lipid homeostasis but induced a small increase in serum ALT in young infertile men with no serious co-morbidities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial registration number<\/jats:title>\n                    <jats:p>NCT03030196.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12020-026-04683-8","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T12:24:05Z","timestamp":1782390245000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effects of a single-dose denosumab on glucose and lipid homeostasis in young infertile men"],"prefix":"10.1007","volume":"91","author":[{"given":"Emil Brink","family":"Wriedt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mads Joon","family":"Jorsal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam Kafai","family":"Yahyavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Juel Mortensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebbe","family":"Eldrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Juul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rune","family":"Holt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Blomberg Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"key":"4683_CR1","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/cen.13038","volume":"85","author":"J Bobjer","year":"2016","unstructured":"J. Bobjer, K. Bogefors, S. Isaksson et al., High prevalence of hypogonadism and associated impaired metabolic and bone mineral status in subfertile men. Clin. Endocrinol. (Oxf). 85, 189\u2013195 (2016). https:\/\/doi.org\/10.1111\/cen.13038","journal-title":"Clin. Endocrinol. (Oxf)"},{"key":"4683_CR2","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1111\/andr.12232","volume":"4","author":"E Ventimiglia","year":"2016","unstructured":"E. Ventimiglia, P. Capogrosso, M. Colicchia et al., Metabolic syndrome in white European men presenting for primary couple\u2019s infertility: investigation of the clinical and reproductive burden. Andrology. 4, 944\u2013951 (2016). https:\/\/doi.org\/10.1111\/andr.12232","journal-title":"Andrology"},{"key":"4683_CR3","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.fertnstert.2015.11.011","volume":"105","author":"ML Eisenberg","year":"2016","unstructured":"M.L. Eisenberg, S. Li, M.R. Cullen, L.C. Baker, Increased risk of incident chronic medical conditions in infertile men: Analysis of United States claims data. Fertil. Steril. 105, 629\u2013636 (2016). https:\/\/doi.org\/10.1016\/j.fertnstert.2015.11.011","journal-title":"Fertil. Steril."},{"key":"4683_CR4","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.bone.2019.03.022","volume":"123","author":"L Juel Mortensen","year":"2019","unstructured":"L. Juel Mortensen, M. Lorenzen, N. J\u00f8rgensen et al., Possible link between FSH and RANKL release from adipocytes in men with impaired gonadal function including Klinefelter syndrome. Bone. 123, 103\u2013114 (2019). https:\/\/doi.org\/10.1016\/j.bone.2019.03.022","journal-title":"Bone"},{"key":"4683_CR5","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1172\/JCI17215","volume":"111","author":"G Eghbali-Fatourechi","year":"2003","unstructured":"G. Eghbali-Fatourechi, S. Khosla, A. Sanyal et al., Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J. Clin. Invest. 111, 1221\u20131230 (2003). https:\/\/doi.org\/10.1172\/JCI17215","journal-title":"J. Clin. Invest."},{"key":"4683_CR6","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","volume":"5","author":"HG Bone","year":"2017","unstructured":"H.G. Bone, R.B. Wagman, M.L. Brandi et al., 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 5, 513\u2013523 (2017). https:\/\/doi.org\/10.1016\/S2213-8587(17)30138-9","journal-title":"Lancet Diabetes Endocrinol."},{"key":"4683_CR7","doi-asserted-by":"publisher","unstructured":"M. Blomberg Jensen, C.H. Andreassen, A. J\u00f8rgensen et al., RANKL regulates male reproductive function. Nat. Commun. 12 (2021). https:\/\/doi.org\/10.1038\/s41467-021-22734-8","DOI":"10.1038\/s41467-021-22734-8"},{"key":"4683_CR8","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1152\/ajpendo.00397.2019.-The","volume":"318","author":"FS Matsuo","year":"2020","unstructured":"F.S. Matsuo, P.H. Cavalcanti De Ara\u00fajo, R. Fonseca Mota et al., RANKL induces beige adipocyte differentiation in preadipocytes. Am. J. Physiol. Endocrinol. Metab. 318, 866\u2013877 (2020). https:\/\/doi.org\/10.1152\/ajpendo.00397.2019.-The","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"4683_CR9","doi-asserted-by":"publisher","unstructured":"T. Ono, M. Hayashi, F. Sasaki, T. Nakashima, (2020) RANKL biology: Bone metabolism, the immune system, and beyond. Inflamm. Regen. 40 https:\/\/doi.org\/10.1186\/s41232-019-0111-3","DOI":"10.1186\/s41232-019-0111-3"},{"key":"4683_CR10","doi-asserted-by":"publisher","unstructured":"L. Zhong, J. Yuan, L. Huang et al., (2020) RANKL Is Involved in Runx2-Triggered Hepatic Infiltration of Macrophages in Mice with NAFLD Induced by a High-Fat Diet. Biomed Res Int 2020:. https:\/\/doi.org\/10.1155\/2020\/6953421","DOI":"10.1155\/2020\/6953421"},{"key":"4683_CR11","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1152\/ajpcell.00285.2015.-Receptor-activator","volume":"310","author":"SS Dufresne","year":"2016","unstructured":"S.S. Dufresne, N.A. Dumont, A. Boulanger-Piette et al., Muscle RANK is a key regulator of Ca 2 storage, SERCA activity, and function of fast-twitch skeletal muscles. Am. J. Physiol. Cell. Physiol. 310, 663\u2013672 (2016). https:\/\/doi.org\/10.1152\/ajpcell.00285.2015.-Receptor-activator","journal-title":"Am. J. Physiol. Cell. Physiol."},{"key":"4683_CR12","doi-asserted-by":"publisher","unstructured":"S.C. Lin, S.H. Tsou, C.Y. Kuo et al., Denosumab Attenuates Glucolipotoxicity-Induced \u03b2-Cell Dysfunction and Apoptosis by Attenuating RANK\/RANKL Signals. Int. J. Mol. Sci. 24 (2023). https:\/\/doi.org\/10.3390\/ijms241210289","DOI":"10.3390\/ijms241210289"},{"key":"4683_CR13","doi-asserted-by":"publisher","unstructured":"N.G. Kondegowda, J. Filipowska, J.-S. Do et al., RANKL\/RANK is required for cytokine-induced beta cell death; osteoprotegerin, a RANKL inhibitor, reverses rodent type 1 diabetes. Sci Adv. 44 (2023). https:\/\/doi.org\/10.1186\/s41232-019-0111-3","DOI":"10.1186\/s41232-019-0111-3"},{"key":"4683_CR14","doi-asserted-by":"publisher","unstructured":"J. Yu, N. Tian, Y. Hu, T. Jin, RANKL\/RANK contributes to the pathological process of type 2 diabetes mellitus through TRAF3 activation of NIK. Int. Immunopharmacol. 142 (2024). https:\/\/doi.org\/10.1016\/j.intimp.2024.113008","DOI":"10.1016\/j.intimp.2024.113008"},{"key":"4683_CR15","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1172\/JCI125915","volume":"129","author":"N Bonnet","year":"2019","unstructured":"N. Bonnet, L. Bourgoin, E. Biver et al., RANKL inhibition improves muscle strength and insulin sensitivity and restores bone mass. J. Clin. Invest. 129, 3214\u20133223 (2019). https:\/\/doi.org\/10.1172\/JCI125915","journal-title":"J. Clin. Invest."},{"key":"4683_CR16","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.cmet.2015.05.021","volume":"22","author":"NG Kondegowda","year":"2015","unstructured":"N.G. Kondegowda, R. Fenutria, I.R. Pollack et al., Osteoprotegerin and Denosumab Stimulate Human Beta Cell Proliferation through Inhibition of the Receptor Activator of NF-\u03baB Ligand Pathway. Cell. Metab. 22, 77\u201385 (2015). https:\/\/doi.org\/10.1016\/j.cmet.2015.05.021","journal-title":"Cell. Metab."},{"key":"4683_CR17","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/nm1166","volume":"11","author":"D Cai","year":"2005","unstructured":"D. Cai, M. Yuan, D.F. Frantz et al., Local and systemic insulin resistance resulting from hepatic activation of IKK-\u03b2 and NF-\u03baB. Nat. Med. 11, 183\u2013190 (2005). https:\/\/doi.org\/10.1038\/nm1166","journal-title":"Nat. Med."},{"key":"4683_CR18","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/nm.3084","volume":"19","author":"S Kiechl","year":"2013","unstructured":"S. Kiechl, J. Wittmann, A. Giaccari et al., Blockade of receptor activator of nuclear factor-\u03baB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus. Nat. Med. 19, 358\u2013363 (2013). https:\/\/doi.org\/10.1038\/nm.3084","journal-title":"Nat. Med."},{"key":"4683_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-073435","author":"H Lyu","year":"2023","unstructured":"H. Lyu, S.S. Zhao, L. Zhang et al., Denosumab and incidence of type 2 diabetes among adults with osteoporosis: population based cohort study. BMJ. (2023). https:\/\/doi.org\/10.1136\/bmj-2022-073435","journal-title":"BMJ"},{"key":"4683_CR20","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-024-07182-6","author":"W Rathmann","year":"2024","unstructured":"W. Rathmann, K. Kostev, Type 2 diabetes incidence in patients initiating denosumab or alendronate treatment: a primary care cohort study. Osteoporos. Int. (2024). https:\/\/doi.org\/10.1007\/s00198-024-07182-6","journal-title":"Osteoporos. Int."},{"key":"4683_CR21","doi-asserted-by":"publisher","first-page":"E2354734","DOI":"10.1001\/jamanetworkopen.2023.54734","volume":"7","author":"HK Huang","year":"2024","unstructured":"H.K. Huang, A.T.M. Chuang, T.C. Liao et al., Denosumab and the Risk of Diabetes in Patients Treated for Osteoporosis. JAMA Netw. Open. 7, E2354734 (2024). https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.54734","journal-title":"JAMA Netw. Open."},{"key":"4683_CR22","doi-asserted-by":"publisher","unstructured":"I. Abe, K. Ochi, Y. Takashi et al., Effect of denosumab, a human monoclonal antibody of receptor activator of nuclear factor kappa-B ligand (RANKL), upon glycemic and metabolic parameters: Effect of denosumab on glycemic parameters. Med. (United States). 98 (2019). https:\/\/doi.org\/10.1097\/MD.0000000000018067","DOI":"10.1097\/MD.0000000000018067"},{"key":"4683_CR23","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s00223-015-0075-5","volume":"98","author":"A Lasco","year":"2016","unstructured":"A. Lasco, N. Morabito, G. Basile et al., Denosumab Inhibition of RANKL and Insulin Resistance in Postmenopausal Women with Osteoporosis. Calcif Tissue Int. 98, 123\u2013128 (2016). https:\/\/doi.org\/10.1007\/s00223-015-0075-5","journal-title":"Calcif Tissue Int."},{"key":"4683_CR24","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae003","author":"SK Ramchand","year":"2024","unstructured":"S.K. Ramchand, R. Hoermann, S. White et al., Cardiometabolic Effects of Denosumab in Premenopausal Women With Breast Cancer Receiving Estradiol Suppression: RCT. J. Clin. Endocrinol. Metab. (2024). https:\/\/doi.org\/10.1210\/clinem\/dgae003","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4683_CR25","doi-asserted-by":"publisher","first-page":"185","DOI":"10.14715\/cmb\/2023.69.8.28","volume":"69","author":"K Wang","year":"2023","unstructured":"K. Wang, L. Gao, C. Liu et al., Denosumab improves glycaemic parameters in postmenopausal osteoporosis patients with combined Type 2 diabetes mellitus. Cell. Mol. Biol. 69, 185\u2013191 (2023). https:\/\/doi.org\/10.14715\/cmb\/2023.69.8.28","journal-title":"Cell. Mol. Biol."},{"key":"4683_CR26","doi-asserted-by":"publisher","unstructured":"N. Napoli, N. Pannacciulli, E. Vittinghoff et al., Effect of denosumab on fasting glucose in women with diabetes or prediabetes from the FREEDOM trial. Diabetes Metab. Res. Rev. 34 (2018). https:\/\/doi.org\/10.1002\/dmrr.2991","DOI":"10.1002\/dmrr.2991"},{"key":"4683_CR27","doi-asserted-by":"publisher","unstructured":"E. Passeri, S. Benedini, E. Costa, S. Corbetta, (2015) A single 60\u00a0mg dose of denosumab might improve hepatic insulin sensitivity in postmenopausal nondiabetic severe osteoporotic women. Int J Endocrinol 2015:. https:\/\/doi.org\/10.1155\/2015\/352858","DOI":"10.1155\/2015\/352858"},{"key":"4683_CR28","doi-asserted-by":"publisher","unstructured":"A. Rossini, S. Frigerio, E. Dozio et al., (2020) Effect of Denosumab on Glucose Homeostasis in Postmenopausal Women with Breast Cancer Treated with Aromatase Inhibitors: A Pilot Study. Int J Endocrinol 2020:. https:\/\/doi.org\/10.1155\/2020\/1809150","DOI":"10.1155\/2020\/1809150"},{"key":"4683_CR29","doi-asserted-by":"publisher","unstructured":"M.M. Weivoda, C.K. Chew, D.G. Monroe et al., Identification of osteoclast-osteoblast coupling factors in humans reveals links between bone and energy metabolism. Nat. Commun. 11 (2020). https:\/\/doi.org\/10.1038\/s41467-019-14003-6","DOI":"10.1038\/s41467-019-14003-6"},{"key":"4683_CR30","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1080\/21556660.2021.1989194","volume":"10","author":"BT Pacheco-Soto","year":"2021","unstructured":"B.T. Pacheco-Soto, R.G. Elguezabal-Rodelo, L.M. Porchia et al., Denosumab improves glucose parameters in patients with impaired glucose tolerance: a systematic review and meta-analysis. J. Drug Assess. 10, 97\u2013105 (2021). https:\/\/doi.org\/10.1080\/21556660.2021.1989194","journal-title":"J. Drug Assess."},{"key":"4683_CR31","doi-asserted-by":"publisher","first-page":"101783","DOI":"10.1016\/j.xcrm.2024.101783","volume":"5","author":"CH Andreassen","year":"2024","unstructured":"C.H. Andreassen, R. Holt, L. Juel Mortensen et al., Denosumab stimulates spermatogenesis in infertile men with preserved Sertoli cell capacity. Cell. Rep. Med. 5, 101783 (2024). https:\/\/doi.org\/10.1016\/j.xcrm.2024.101783","journal-title":"Cell. Rep. Med."},{"key":"4683_CR32","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/s41416-022-01810-w","volume":"127","author":"CH Andreassen","year":"2022","unstructured":"C.H. Andreassen, M. Lorenzen, J.E. Nielsen et al., RANKL regulates testicular cancer growth and Denosumab treatment has suppressive effects on GCNIS and advanced seminoma. Br. J. Cancer. 127, 408\u2013421 (2022). https:\/\/doi.org\/10.1038\/s41416-022-01810-w","journal-title":"Br. J. Cancer"},{"key":"4683_CR33","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.cca.2017.03.002","volume":"468","author":"T S\u00f8eborg","year":"2017","unstructured":"T. S\u00f8eborg, H. Frederiksen, T.H. Johannsen et al., Isotope-dilution TurboFlow-LC-MS\/MS method for simultaneous quantification of ten steroid metabolites in serum. Clin. Chim. Acta. 468, 180\u2013186 (2017). https:\/\/doi.org\/10.1016\/j.cca.2017.03.002","journal-title":"Clin. Chim. Acta"},{"key":"4683_CR34","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1001\/jama.2015.19394","volume":"315","author":"MA Detry","year":"2016","unstructured":"M.A. Detry, Y. Ma, Analyzing Repeated Measurements Using Mixed Models. JAMA 315, 407 (2016). https:\/\/doi.org\/10.1001\/jama.2015.19394","journal-title":"JAMA"},{"key":"4683_CR35","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1080\/10543406.2013.856024","volume":"24","author":"I Lipkovich","year":"2014","unstructured":"I. Lipkovich, A. Dmitrienko, Strategies for identifying predictive biomarkers and subgroups with enhanced treatment effect in clinical trials using SIDES. J. Biopharm. Stat. 24, 130\u2013153 (2014). https:\/\/doi.org\/10.1080\/10543406.2013.856024","journal-title":"J. Biopharm. Stat."},{"key":"4683_CR36","doi-asserted-by":"publisher","unstructured":"C. Argano, L. Mirarchi, S. Amodeo et al., (2023) The Role of Vitamin D and Its Molecular Bases in Insulin Resistance, Diabetes, Metabolic Syndrome, and Cardiovascular Disease: State of the Art. Int. J. Mol. Sci. 24 https:\/\/doi.org\/10.3390\/ijms242015485","DOI":"10.3390\/ijms242015485"},{"key":"4683_CR37","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1210\/clinem\/dgab667","volume":"107","author":"R Holt","year":"2022","unstructured":"R. Holt, J.H. Petersen, E. Dinsdale et al., Vitamin D Supplementation Improves Fasting Insulin Levels and HDL Cholesterol in Infertile Men. J. Clin. Endocrinol. Metab. 107, 98\u2013108 (2022). https:\/\/doi.org\/10.1210\/clinem\/dgab667","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4683_CR38","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s13679-023-00505-4","volume":"12","author":"ID Vachliotis","year":"2023","unstructured":"I.D. Vachliotis, S.A. Polyzos, Osteoprotegerin\/Receptor Activator of Nuclear Factor-Kappa B Ligand\/Receptor Activator of Nuclear Factor-Kappa B Axis in Obesity, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease. Curr. Obes. Rep. 12, 147\u2013162 (2023) https:\/\/doi.org\/10.1007\/s13679-023-00505-4","journal-title":"Curr. Obes. Rep."},{"key":"4683_CR39","volume-title":"National Institute of Diabetes and Digestive and Kidney Diseases","author":"Bethesda (MD)","year":"2017","unstructured":"Bethesda (MD), National Institute of Diabetes and Digestive and Kidney Diseases (Clinical and Research Information on Drug-Induced Liver Injury [Internet], Denosumab, LiverTox, 2017)"},{"key":"4683_CR40","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s41574-020-0341-0","volume":"16","author":"P Chotiyarnwong","year":"2020","unstructured":"P. Chotiyarnwong, E.V. McCloskey, Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment. Nat. Rev. Endocrinol. 16, 437\u2013447 (2020) https:\/\/doi.org\/10.1038\/s41574-020-0341-0","journal-title":"Nat. Rev. Endocrinol."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-026-04683-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-026-04683-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-026-04683-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T12:24:06Z","timestamp":1782390246000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-026-04683-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,25]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4683"],"URL":"https:\/\/doi.org\/10.1007\/s12020-026-04683-8","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,25]]},"assertion":[{"value":"15 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The trial was approved by the Danish Medicines Agency (approval no. 2016-003546-84), and the local ethical committee (journal no: H-15001992).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Consent to publish was obtained from all participants along with consent to participate.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"MBJ holds two patents on the use of RANKL inhibitors to treat male infertility, and a spin out company (XY Therapeutics) has been generated based on this IP. All other authors state no conflicts of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"215"}}